Tilray Brands (TLRY) trades at $2.93, a fresh 52-week low, after losing 28.2% in a month and falling 30.7% from its September 22, 2026 close of $4.23. The balance of evidence leans negative with high conviction: the daily trend runs with the weekly downtrend and the stock trails both the S&P 500 and the healthcare sector. Revenue is growing, but the market is paying nothing for it.
Why it matters
The event that framed the move was the quarterly report. SEC EDGAR shows first-quarter fiscal 2027 revenue of $257.1 million, up 23% from a year earlier, against a net loss of $43.1 million and a loss of $0.32 per share. Growth that does not reach the bottom line is the pattern the market has been punishing, and the filing gave buyers no reason to change that.
The reaction since the report has been steady selling, not a one-day shock. The stock sits well below its 50-day average of $4.06 and its 200-day average of $5.70. Over the last five days it fell 6.7% while the S&P 500 rose about 0.2% and XLV, the healthcare sector fund, rose 2.7%. That leaves the stock 9.4 points behind its sector in five days, so this is a stock-specific move, not a market or sector one. Today's 3.3% drop came on volume 26% below the 20-day average. Nobody is rushing to sell, but nobody is stepping in either.
The argument over TLRY has two sides, and no debate articles are on file for it. The constructive side points to the 23% revenue growth, to the company's plan to invest over £50 million in the BrewDog pubs and beers it bought for £33 million, as The Guardian reports, and to a sector backdrop where Forbes describes banking momentum after medical cannabis moved to Schedule III. The cautious side points to the $43.1 million quarterly loss, to creditors owed about £190 million who will not be repaid in the BrewDog deal, and to a price that keeps making lows. The news does not fully explain the pace of this decline, and the price action is running ahead of anything in the filings.
Valuation shows how far apart price and opinion are. Nine analysts rate the stock a buy, with a mean price target of $5.89, a low of $4.00 and a high of $12.00. The stock trades 50.2% below that mean and below even the lowest target. Targets this far above the price usually mean analysts have not caught up with the market, not that the market is wrong.
What the evidence says
The long-term thesis is broken, and the stock is in a late, heavy phase of a downtrend. Price is below its 40-week average and below its 10-week average. It has fallen from a 52-week high of $149.00 to $2.93, within pennies of the year's low. Against the S&P 500 it has lagged by 52.3% over 200 days, and the long-term picture does not show a stock that has found a floor.
For the next two to six weeks the balance of evidence leans negative, and conviction is high at three of four points. The daily trend runs with the weekly downtrend. The stock lags the S&P 500 by 28.1% over 50 days and lags XLV by 31.1%. Each rally has run into sellers near $3.00, and the stock now sits just under that level.
The strongest case against this reading is that the stock is deeply oversold, with a 14-day RSI of 23, and that selling volume is fading. Oversold readings in a downtrend often produce sharp bounces, and a bounce toward $3.50 or the 50-day average at $4.06 would not surprise anyone. That is why conviction is not a full four of four. It does not tip the balance, because an oversold reading says a bounce is likely, not that the trend has turned. The weekly trend remains down until price recovers far more ground than a bounce would give.
Levels that matter
The structure holds below $3.00, a round number where sellers have shown up on rallies. Above it sit $3.50 and the 50-day average at $4.06. The weekly trend would end only above $4.85, a swing zone just under $4.94, where the stock turned in the past. That is roughly the area it has to recover before the downtrend can be called over.
The breakout level is a daily close below $2.50, a round-number support. From there the next target is $2.00, also a round number. The stop for that move is $3.04, which is $3.00 plus a quarter of the 14-day average true range of $0.17. Measured from $2.50, the math gives 0.9 to 1, well short of the 3 to 1 that makes a breakout worth the risk. It would take a target far below $2.00, or a stop much closer to $2.50, to get there, and neither is on the map today.
What would change the picture
A weekly close above $4.85 would be the first sign that buyers are back and that the downtrend is over. The non-price fact that would most likely cause it is a quarterly report showing the net loss shrinking from $43.1 million while revenue keeps growing. That would mean the growth is starting to reach the bottom line, and it is the one thing the current price assumes will not happen.
What to watch
- Earnings: the next report is due January 7, 2027. The number that matters is the net loss against $43.1 million, with revenue growth compared to the 23% just reported.
- Sector events: further federal steps on cannabis rescheduling and banking access, which Forbes covers, tend to move the stock before its own news. So does the follow-through on BrewDog spending.
- Price: a daily close below $2.50, or a rebound that fails again at $3.00.
- Valuation: at $2.93 the stock trades 50.2% below the $5.89 mean target and below the $4.00 low. Either the targets fall or the price has overshot, and earnings will show which.